For a quick and easy start, request free samples.
CSS Do not remove
Dexcom G7 15 Day: A win for adult patients with diabetes, regardless of insulin use*,1
Dexcom G7 15 Day: gives your type 2 diabetes patients on insulin more time in range using less insulin.2
2.4% reduction in A1C from baseline at 6 months†,3
Dexcom CGM is clinically proven to lower A1C1
Changes in A1C through 1 year
Study design: Real-world study of 74,679 type 2 diabetes adults, including 1375 basal insulin users and 3122 prandial insulin users. A1C values analyzed pre-index, 3, 6, and 12 months post-index, represented as mean ±SEM. Significant improvements in A1C were observed at 3 months and sustained throughout the study period (‡P<.0001).
Key findings in patients with type 2 diabetes on insulin
Real-world study showed statistically significant A1C reduction at 3 months and sustained at 1 year§,1
CGM was associated with a reduction in hospitalizations and emergency room visits1
CGM decreased A1C across all therapy types (BIT and PIT) regardless of medication changes||,1
Even for patients who meet their A1C goals (<7%), CGM provides 24-hour insights to ensure every glucose excursion can be addressed.
Compare glycemic outcomes with CGM vs. BGM in adults with insulin-treated type 2 diabetes2
CGM-derived metrics at baseline and 12-month follow-up.
Study design: A 12-month, single-center, open-label randomized controlled trial comparing CGM with BGM in 76 adults with insulin-treated type 2 diabetes. Participants were randomized 1:1, with the primary outcome being change in time in range (70-180 mg/dL) from baseline to 12 months, measured by blinded CGM. Secondary outcomes included A1C, insulin dose, weight, and patient-reported outcomes (¶P<.05).2
The wins add up every day
+3.6 more hours
in range per day2
"a game changer"
Study participants said Dexcom CGM is “a game changer” for motivating better habits2
2.4% reduction in A1C
from baseline at 6 months†,3
Why CGM for patients with type 2 diabetes on insulin?
ADA guidelines recommend CGM as an option for adult patients with type 2 diabetes whether they use4:
- Insulin
- Non-insulin injectable glucose-lowering medications
- Oral glucose-lowering medications
ONLY 13%
of patients with TYPE 2 DIABETES have adopted CGM6
CGM reveals dangerous hyper- and hypogylcemic excursions6
Blood glucose monitoring (BGM) doesn’t reveal the full story. CGM provides the complete 24-hour picture to help your patients address spikes or troughs BGM can miss.
Illustrative model of a 24‑hour blood glucose profile; not derived from an actual patient dataset.
Ready to Prescribe
Patient Profiles
See how Dexcom G7 15 Day works in patient types
Coverage and Affordability
Extensive coverage through a broad range of commercial and Medicare plans**
A1C=hemoglobin A1C; ADA=American Diabetes Association; BGM=blood glucose monitoring; BIT=basal insulin therapy; CGM=continuous glucose monitoring; CPT=Current Procedural Terminology; DME=durable medical equipment; PIT=prandial insulin therapy; SEM=standard error of mean.
*In a retrospective study, diabetes-related hospitalizations reduced 12 months after CGM use: Non-insulin (-31%) Basal insulin (-48%) Prandial insulin (-53%).1 †After 6 months, for patients with type 2 diabetes who initiated Dexcom CGM in primary care. §This retrospective cohort analysis used Optum's deidentified Market Clarity data of >79 million people to evaluate CGM use in people with type 2 diabetes who were treated with non-insulin (NIT), basal insulin (BIT) and prandial insulin therapy (PIT). ||Retrospective cohort analysis using Optum deidentified Market Clarity data of >79 million people to evaluate CGM use in people with type 2 diabetes. #Individual prices may vary depending on insurance coverage. Under Medicare’s DME fee schedule, reimbursement and coinsurance for CGMs using CPT codes A4239 and E2103 are the same, regardless of CGM brand.
1 Garg SK, et al. Diabetes Obes Metab. 2024;26(11):5202-5210. 2 Lind N, et al. Diabetes Care. 2024;47(5):881-889. 3 Grace TP, et al. Clin Diabetes. 2024;42(4):540-546. 4 Diabetes Technology: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S146-S166. 5 Mayberry LS, et al. J Gen Intern Med. 2023;38(11):2546-2552. 6 Dexcom G7 15 Day User Guide.
